Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CardioMEMS Inc.

This article was originally published in Start Up

Executive Summary

CardioMEMS has developed a wireless, implantable pressure sensor, to help physicians "watch and wait" after endovascular AAA repair. The same technology forms the foundation for a future continuous monitoring platform in congestive heart failure.

You may also be interested in...



Thriving When The Device IPO Window Closes

The general economic malaise closed the IPO window for medical device companies, forcing many to withdraw their public financing plans. Companies are adopting various financing and operational strategies to make a best of a bad situation.

Filling in the Gaps in AAA Repair

The first stent grafts created a market for the endovascular repair of abdominal aortic aneurysms. They also created new problems for start-ups to overcome. New companies have risen to the problem of avoiding endoleaks, with new stent graft designs and attachment systems, and also solutions for continuous monitoring.

Remote Possibilities

Companies with new, often implantable devices that enable the remote monitoring of patients aim to enable a new, more efficient kind of disease management. However, one of the biggest hurdles to adoption of disease management to date has been lack of reimbursement. The patients that can most benefit from disease management--sufferers of congestive heart failure, for example--tend to be elderly people that are covered by Medicare, which has no mechanisms to reimburse for disease management. So, beyond the usual hurdles that device companies face, of working the kinks out of technology and proving its clinical value to physicians, patient monitoring companies also need to find the right delivery model that helps them get paid for their technology.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel